168 related articles for article (PubMed ID: 21845450)
1. [Fingolimod treatment for multiple sclerosis patients. Infectiological aspects and recommendations for vaccinations].
Winkelmann A; Löbermann M; Reisinger EC; Zettl UK
Nervenarzt; 2012 Feb; 83(2):236-42. PubMed ID: 21845450
[TBL] [Abstract][Full Text] [Related]
2. T-cell response against varicella-zoster virus in fingolimod-treated MS patients.
Ricklin ME; Lorscheider J; Waschbisch A; Paroz C; Mehta SK; Pierson DL; Kuhle J; Fischer-Barnicol B; Sprenger T; Lindberg RL; Kappos L; Derfuss T
Neurology; 2013 Jul; 81(2):174-81. PubMed ID: 23700335
[TBL] [Abstract][Full Text] [Related]
3. Oral fingolimod (gilenya) for multiple sclerosis.
Med Lett Drugs Ther; 2010 Dec; 52(1353-1354):98-9. PubMed ID: 21344782
[No Abstract] [Full Text] [Related]
4. Delayed fingolimod-associated asystole.
Espinosa PS; Berger JR
Mult Scler; 2011 Nov; 17(11):1387-9. PubMed ID: 21652609
[TBL] [Abstract][Full Text] [Related]
5. Reactivation of herpesvirus under fingolimod: A case of severe herpes simplex encephalitis.
Pfender N; Jelcic I; Linnebank M; Schwarz U; Martin R
Neurology; 2015 Jun; 84(23):2377-8. PubMed ID: 25957334
[No Abstract] [Full Text] [Related]
6. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
Calabresi PA; Radue EW; Goodin D; Jeffery D; Rammohan KW; Reder AT; Vollmer T; Agius MA; Kappos L; Stites T; Li B; Cappiello L; von Rosenstiel P; Lublin FD
Lancet Neurol; 2014 Jun; 13(6):545-56. PubMed ID: 24685276
[TBL] [Abstract][Full Text] [Related]
7. Fingolimod for multiple sclerosis.
Drug Ther Bull; 2012 Feb; 50(2):18-20. PubMed ID: 22329953
[TBL] [Abstract][Full Text] [Related]
8. Trial watch: Phase III promise for oral multiple sclerosis therapy.
Nat Rev Drug Discov; 2009 Feb; 8(2):98. PubMed ID: 19180099
[No Abstract] [Full Text] [Related]
9. The real-life experience with cardiovascular complications in the first dose of fingolimod for multiple sclerosis.
Fragoso YD; Arruda CC; Arruda WO; Brooks JB; Damasceno A; Damasceno CA; Finkelsztejn A; Finkelsztejn J; Gama PD; Giacomo MC; Gomes S; Goncalves MV; Matta AP; de Morais MM; Oliveira EM; Ribeiro Y; Sato HK; Tauil CB
Arq Neuropsiquiatr; 2014 Sep; 72(9):712-4. PubMed ID: 25252236
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis.
Chun J; Hartung HP
Clin Neuropharmacol; 2010; 33(2):91-101. PubMed ID: 20061941
[TBL] [Abstract][Full Text] [Related]
11. Oral fingolimod for the treatment of patients with relapsing forms of multiple sclerosis.
Singer B; Ross AP; Tobias K
Int J Clin Pract; 2011 Aug; 65(8):887-95. PubMed ID: 21679286
[TBL] [Abstract][Full Text] [Related]
12. Overview and safety of fingolimod hydrochloride use in patients with multiple sclerosis.
Ward MD; Jones DE; Goldman MD
Expert Opin Drug Saf; 2014 Jul; 13(7):989-98. PubMed ID: 24935480
[TBL] [Abstract][Full Text] [Related]
13. [Fingolimod in the treatment of multiple sclerosis. Novelties presented at the annual congress of the American Academy of Neurology (Toronto, April 2010)].
Rabasseda X
Drugs Today (Barc); 2010 Jul; 46 Suppl D():1-14. PubMed ID: 20820453
[TBL] [Abstract][Full Text] [Related]
14. Fingolimod-associated amenorrhea: a report of three cases.
Alroughani R
Mult Scler; 2014 Oct; 20(12):1662-4. PubMed ID: 24515730
[TBL] [Abstract][Full Text] [Related]
15. [Fingolimod treatment in multiple sclerosis].
Tanaka M
Nihon Rinsho; 2014 Nov; 72(11):2010-4. PubMed ID: 25518386
[TBL] [Abstract][Full Text] [Related]
16. Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial.
Laroni A; Brogi D; Morra VB; Guidi L; Pozzilli C; Comi G; Lugaresi A; Turrini R; Raimondi D; Uccelli A; Mancardi GL;
BMC Neurol; 2014 Apr; 14():65. PubMed ID: 24690227
[TBL] [Abstract][Full Text] [Related]
17. Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management.
Arvin AM; Wolinsky JS; Kappos L; Morris MI; Reder AT; Tornatore C; Gershon A; Gershon M; Levin MJ; Bezuidenhoudt M; Putzki N
JAMA Neurol; 2015 Jan; 72(1):31-9. PubMed ID: 25419615
[TBL] [Abstract][Full Text] [Related]
18. Fingolimod: an oral disease-modifying therapy for relapsing multiple sclerosis.
Yeh EA; Weinstock-Guttman B
Adv Ther; 2011 Apr; 28(4):270-8. PubMed ID: 21394595
[TBL] [Abstract][Full Text] [Related]
19. [Infections and fingolimod].
Cervera C
Rev Neurol; 2012 Aug; 55(4):227-37. PubMed ID: 22829086
[TBL] [Abstract][Full Text] [Related]
20. [A plan for risk management in the treatment of multiple sclerosis with gilenia (fingolimod)].
Popova NF
Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(2 Pt 2):110-3. PubMed ID: 21916166
[No Abstract] [Full Text] [Related]
[Next] [New Search]
